Tracleer is a drug owned by Actelion. It contains the active ingredient bosentan and is available in tablet and suspension forms for oral use. Tracleer was first authorized for market use on 5th September, 2017.
The generic version of Tracleer is likely to be released after 28th December, 2027, once the last patent expires.
Tracleer, with its active ingredient bosentan, is commonly used for treating conditions related to the heart and blood vessels.
Tracleer holds a total of 2 patents, none of which have expired as of now. The last patent is due to expire on 28th December, 2027, opening the way for Tracleer generic. Below are the details of the patent: